Employing novel animal models in the design of clinically efficacious GPCR ligands

Current Opinion in Cell Biology

Volumn 27, Issue 1, 2014, Pages 117-125

  Bradley, Sophie J ^a   Riaz, Sajjad A ^a   Tobin, Andrew B ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR LIGAND; LIGAND; UNCLASSIFIED DRUG;

BINDING SITE; CLINICAL EFFECTIVENESS; DRUG DESIGN; NONHUMAN; PHARMACOLOGICAL SCIENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; STIMULUS; TRANSGENIC ORGANISM; VALIDATION PROCESS; AGONISTS; ANIMAL; ANIMAL MODEL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DRUG EFFECTS; HUMAN; METABOLISM; PHARMACOLOGY; PROCEDURES; REPRODUCIBILITY; TRANSGENIC ANIMAL;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; DRUG DESIGN; HUMANS; LIGANDS; MODELS, ANIMAL; PHARMACOLOGY; RECEPTORS, G-PROTEIN-COUPLED; REPRODUCIBILITY OF RESULTS; SIGNAL TRANSDUCTION;

EID: 84891436049     PISSN: 09550674     EISSN: 18790410     Source Type: Journal    
DOI: 10.1016/j.ceb.2013.12.002     Document Type: Review

References (78)

1. Jacoby E., Bouhelal R., Gerspacher M., Seuwen K. The 7 tm g-protein-coupled receptor target family. ChemMedChem 2006, 1:761-782.
2. Congreve M., Langmead C.J., Mason J.S., Marshall F.H. Progress in structure based drug design for g protein-coupled receptors. J Med Chem 2011, 54:4283-4311.
3. Hopkins A.L., Groom C.R. The druggable genome. Nat Rev Drug Discov 2002, 1:727-730.
4. Overington J.P., Al-Lazikani B., Hopkins A.L. How many drug targets are there?. Nat Rev Drug Discov 2006, 5:993-996.
5. Schlyer S., Horuk R. I want a new drug: G-protein-coupled receptors in drug development. Drug Discov Today 2006, 11:481-493.
6. Lagerstrom M.C., Schioth H.B. Structural diversity of G protein-coupled receptors and significance for drug discovery. Nat Rev Drug Discov 2008, 7:339-357.
7. Arrowsmith J. Trial watch: phase ii failures: 2008-2010. Nat Rev Drug Discov 2011, 10:328-329.
8. Arrowsmith J. Trial watch: phase iii and submission failures: 2007-2010. Nat Rev Drug Discov 2011, 10:87.
9. Kenakin T., Williams M. Defining and characterizing drug/compound function. Biochem Pharmacol 2013.
10. Wootten D., Christopoulos A., Sexton P.M. Emerging paradigms in gpcr allostery: implications for drug discovery. Nat Rev Drug Discov 2013, 12:630-644.
11. Bonner T.I. The molecular basis of muscarinic receptor diversity. Trends Neurosci 1989, 12:148-151.
12. Eglen R.M., Watson N. Selective muscarinic receptor agonists and antagonists. Pharmacol Toxicol 1996, 78:59-68.
13. Eglen R.M., Choppin A., Dillon M.P., Hegde S. Muscarinic receptor ligands and their therapeutic potential. Curr Opin Chem Biol 1999, 3:426-432.
14. Digby G.J., Shirey J.K., Conn P.J. Allosteric activators of muscarinic receptors as novel approaches for treatment of CNS disorders. Mol BioSyst 2010, 6:1345-1354.
15. Gregory K.J., Sexton P.M., Christopoulos A. Allosteric modulation of muscarinic acetylcholine receptors. Curr Neuropharmacol 2007, 5:157-167.
16. Kuduk S.D., Beshore D.C. Novel m(1) allosteric ligands: a patent review. Expert Opin Ther Patents 2012, 22:1385-1398.
17. Ma L., Seager M.A., Wittmann M., Jacobson M., Bickel D., Burno M., Jones K., Graufelds V.K., Xu G., Pearson M., McCampbell A., et al. Selective activation of the m1 muscarinic acetylcholine receptor achieved by allosteric potentiation. Proc Natl Acad Sci U S A 2009, 106:15950-15955.
18. Canals M., Lane J.R., Wen A., Scammells P.J., Sexton P.M., Christopoulos A. A Monod-Wyman-Changeux mechanism can explain G protein-coupled receptor (GPCR) allosteric modulation. J Biol Chem 2012, 287:650-659.
19. Conn P.J., Christopoulos A., Lindsley C.W. Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders. Nat Rev Drug Discov 2009, 8:41-54.
20. Fisher A., Heldman E., Gurwitz D., Haring R., Karton Y., Meshulam H., Pittel Z., Marciano D., Brandeis R., Sadot E., Barg Y., et al. M1 agonists for the treatment of Alzheimer's disease. Novel properties and clinical update. Ann N Y Acad Sci 1996, 777:189-196.
21. Fisher A., Michaelson D.M., Brandeis R., Haring R., Chapman S., Pittel Z. M1 muscarinic agonists as potential disease-modifying agents in Alzheimer's disease. Rationale and perspectives. Ann N Y Acad Sci 2000, 920:315-320.
22. Kenakin T. Allosteric drugs and seven transmembrane receptors. Curr Top Med Chem 2013, 13:5-13.
23. Rajagopal S., Ahn S., Rominger D.H., Gowen-MacDonald W., Lam C.M., Dewire S.M., Violin J.D., Lefkowitz R.J. Quantifying ligand bias at seven-transmembrane receptors. Mol Pharmacol 2011, 80:367-377.
24. Kenakin T. Agonist-receptor efficacy. II. Agonist trafficking of receptor signals. Trends Pharmacol Sci 1995, 16:232-238.
25. Kenakin T., Christopoulos A. Signalling bias in new drug discovery: detection, quantification and therapeutic impact. Nat Rev Drug Discov 2013, 12:205-216.
26. Kenakin T.P. Biased signalling and allosteric machines: new vistas and challenges for drug discovery. Br J Pharmacol 2012, 165:1659-1669.
27. Wess J. Muscarinic acetylcholine receptor knockout mice: novel phenotypes and clinical implications. Annu Rev Pharmacol Toxicol 2004, 44:423-450.
28. Wess J., Eglen R.M., Gautam D. Muscarinic acetylcholine receptors: mutant mice provide new insights for drug development. Nat Rev Drug Discov 2007, 6:721-733.
29. Coward P., Wada H.G., Falk M.S., Chan S.D., Meng F., Akil H., Conklin B.R. Controlling signaling with a specifically designed Gi-coupled receptor. Proc Natl Acad Sci U S A 1998, 95:352-357.
30. Redfern C.H., Coward P., Degtyarev M.Y., Lee E.K., Kwa A.T., Hennighausen L., Bujard H., Fishman G.I., Conklin B.R. Conditional expression and signaling of a specifically designed gi-coupled receptor in transgenic mice. Nat Biotechnol 1999, 17:165-169.
31. Scearce-Levie K., Lieberman M.D., Elliott H.H., Conklin B.R. Engineered g protein coupled receptors reveal independent regulation of internalization, desensitization and acute signaling. BMC Biol 2005, 3:3.
32. Chang W.C., Ng J.K., Nguyen T., Pellissier L., Claeysen S., Hsiao E.C., Conklin B.R. Modifying ligand-induced and constitutive signaling of the human 5-ht4 receptor. PLoS ONE 2007, 2:e1317.
33. Claeysen S., Joubert L., Sebben M., Bockaert J., Dumuis A. A single mutation in the 5-ht4 receptor (5-ht4-r d100(3.32)a) generates a Gs-coupled receptor activated exclusively by synthetic ligands (RASSL). J Biol Chem 2003, 278:699-702.
34. Hsiao E.C., Boudignon B.M., Chang W.C., Bencsik M., Peng J., Nguyen T.D., Manalac C., Halloran B.P., Conklin B.R., Nissenson R.A. Osteoblast expression of an engineered Gs-coupled receptor dramatically increases bone mass. Proc Natl Acad Sci U S A 2008, 105:1209-1214.
35. Conklin B.R., Hsiao E.C., Claeysen S., Dumuis A., Srinivasan S., Forsayeth J.R., Guettier J.M., Chang W.C., Pei Y., McCarthy K.D., Nissenson R.A., et al. Engineering GPCR signaling pathways with RASSLs. Nat Methods 2008, 5:673-678.
36. Armbruster B.N., Li X., Pausch M.H., Herlitze S., Roth B.L. Evolving the lock to fit the key to create a family of G protein-coupled receptors potently activated by an inert ligand. Proc Natl Acad Sci U S A 2007, 104:5163-5168.
37. Guettier J.M., Gautam D., Scarselli M., Ruiz de Azua I., Li J.H., Rosemond E., Ma X., Gonzalez F.J., Armbruster B.N., Lu H., Roth B.L., et al. A chemical-genetic approach to study G protein regulation of beta cell function in vivo. Proc Natl Acad Sci U S A 2009, 106:19197-19202.
38. Jain S., Ruiz de Azua I., Lu H., White M.F., Guettier J.M., Wess J. Chronic activation of a designer g(q)-coupled receptor improves beta cell function. J Clin Investig 2013, 123:1750-1762.
39. Alexander G.M., Rogan S.C., Abbas A.I., Armbruster B.N., Pei Y., Allen J.A., Nonneman R.J., Hartmann J., Moy S.S., Nicolelis M.A., McNamara J.O., et al. Remote control of neuronal activity in transgenic mice expressing evolved G protein-coupled receptors. Neuron 2009, 63:27-39.
40. Garner A.R., Rowland D.C., Hwang S.Y., Baumgaertel K., Roth B.L., Kentros C., Mayford M. Generation of a synthetic memory trace. Science 2012, 335:1513-1516.
41. Parnaudeau S., O'Neill P.K., Bolkan S.S., Ward R.D., Abbas A.I., Roth B.L., Balsam P.D., Gordon J.A., Kellendonk C. Inhibition of mediodorsal thalamus disrupts thalamofrontal connectivity and cognition. Neuron 2013, 77:1151-1162.
42. Kong D., Tong Q., Ye C., Koda S., Fuller P.M., Krashes M.J., Vong L., Ray R.S., Olson D.P., Lowell B.B. Gabaergic rip-cre neurons in the arcuate nucleus selectively regulate energy expenditure. Cell 2012, 151:645-657.
43. Violin J.D., Lefkowitz R.J. Beta-arrestin-biased ligands at seven-transmembrane receptors. Trends Pharmacol Sci 2007, 28:416-422.
44. Kong K.C., Butcher A.J., McWilliams P., Jones D., Wess J., Hamdan F.F., Werry T., Rosethorne E.M., Charlton S.J., Munson S.E., Cragg H.A., et al. M3-muscarinic receptor promotes insulin release via receptor phosphorylation/arrestin-dependent activation of protein kinase d1. Proc Natl Acad Sci U S A 2010, 107:21181-21186.
45. Poulin B., Butcher A., McWilliams P., Bourgognon J.M., Pawlak R., Kong K.C., Bottrill A., Mistry S., Wess J., Rosethorne E.M., Charlton S.J., et al. The m3-muscarinic receptor regulates learning and memory in a receptor phosphorylation/arrestin-dependent manner. Proc Natl Acad Sci U S A 2010, 107:9440-9445.
46. Wei H., Ahn S., Shenoy S.K., Karnik S.S., Hunyady L., Luttrell L.M., Lefkowitz R.J. Independent beta-arrestin 2 and g protein-mediated pathways for angiotensin ii activation of extracellular signal-regulated kinases 1 and 2. Proc Natl Acad Sci U S A 2003, 100:10782-10787.
47. Holloway A.C., Qian H., Pipolo L., Ziogas J., Miura S., Karnik S., Southwell B.R., Lew M.J., Thomas W.G. Side-chain substitutions within angiotensin ii reveal different requirements for signaling, internalization, and phosphorylation of type 1a angiotensin receptors. Mol Pharmacol 2002, 61:768-777.
48. Ahn S., Shenoy S.K., Wei H., Lefkowitz R.J. Differential kinetic and spatial patterns of beta-arrestin and g protein-mediated erk activation by the angiotensin ii receptor. J Biol Chem 2004, 279:35518-35525.
49. Boerrigter G., Soergel D.G., Violin J.D., Lark M.W., Burnett J.C. Trv120027, a novel beta-arrestin biased ligand at the angiotensin ii type i receptor, unloads the heart and maintains renal function when added to furosemide in experimental heart failure. Circ Heart Fail 2012, 5:627-634.
50. Kendall R.T., Strungs E.G., Rachidi S.M., Lee M.H., El-Shewy H.M., Luttrell D.K., Janech M.G., Luttrell L.M. The beta-arrestin pathway-selective type 1a angiotensin receptor (at1a) agonist [sar1,ile4,ile8]angiotensin ii regulates a robust g protein-independent signaling network. J Biol Chem 2011, 286:19880-19891.
51. Gautam D., Ruiz de Azua I., Li J.H., Guettier J.M., Heard T., Cui Y., Lu H., Jou W., Gavrilova O., Zawalich W.S., Wess J. Beneficial metabolic effects caused by persistent activation of beta-cell m3 muscarinic acetylcholine receptors in transgenic mice. Endocrinology 2010, 151:5185-5194.
52. Gautam D., Han S.J., Duttaroy A., Mears D., Hamdan F.F., Li J.H., Cui Y., Jeon J., Wess J. Role of the m3 muscarinic acetylcholine receptor in beta-cell function and glucose homeostasis. Diabetes Obes Metab 2007, 9(Suppl 2):158-169.
53. Gautam D., Han S.J., Hamdan F.F., Jeon J., Li B., Li J.H., Cui Y., Mears D., Lu H., Deng C., Heard T., et al. A critical role for beta cell m3 muscarinic acetylcholine receptors in regulating insulin release and blood glucose homeostasis in vivo. Cell Metab 2006, 3:449-461.
54. Duttaroy A., Zimliki C.L., Gautam D., Cui Y., Mears D., Wess J. Muscarinic stimulation of pancreatic insulin and glucagon release is abolished in m3 muscarinic acetylcholine receptor-deficient mice. Diabetes 2004, 53:1714-1720.
55. Gilon P., Henquin J.C. Mechanisms and physiological significance of the cholinergic control of pancreatic beta-cell function. Endocr Rev 2001, 22:565-604.
56. Gromada J., Hughes T.E. Ringing the dinner bell for insulin: muscarinic m3 receptor activity in the control of pancreatic beta cell function. Cell Metab 2006, 3:390-392.
57. Ruiz de Azua I., Scarselli M., Rosemond E., Gautam D., Jou W., Gavrilova O., Ebert P.J., Levitt P., Wess J. Rgs4 is a negative regulator of insulin release from pancreatic beta-cells in vitro and in vivo. Proc Natl Acad Sci U S A 2010, 107:7999-8004.
58. Sumara G., Formentini I., Collins S., Sumara I., Windak R., Bodenmiller B., Ramracheya R., Caille D., Jiang H., Platt K.A., Meda P., et al. Regulation of pkd by the mapk p38delta in insulin secretion and glucose homeostasis. Cell 2009, 136:235-248.
59. Christensen G.L., Kelstrup C.D., Lyngso C., Sarwar U., Bogebo R., Sheikh S.P., Gammeltoft S., Olsen J.V., Hansen J.L. Quantitative phosphoproteomics dissection of seven-transmembrane receptor signaling using full and biased agonists. Mol Cell Proteom 2010, 9:1540-1553.
60. Del Prato S., Marchetti P., Bonadonna R.C. Phasic insulin release and metabolic regulation in type 2 diabetes. Diabetes 2002, 51(Suppl 1):S109-S116.
61. Nesher R., Cerasi E. Modeling phasic insulin release: immediate and time-dependent effects of glucose. Diabetes 2002, 51(Suppl 1):S53-S59.
62. Akhter S.A., Luttrell L.M., Rockman H.A., Iaccarino G., Lefkowitz R.J., Koch W.J. Targeting the receptor-gq interface to inhibit in vivo pressure overload myocardial hypertrophy. Science 1998, 280:574-577.
63. Communal C., Singh K., Pimentel D.R., Colucci W.S. Norepinephrine stimulates apoptosis in adult rat ventricular myocytes by activation of the beta-adrenergic pathway. Circulation 1998, 98:1329-1334.
64. Violin J.D., DeWire S.M., Yamashita D., Rominger D.H., Nguyen L., Schiller K., Whalen E.J., Gowen M., Lark M.W. Selectively engaging beta-arrestins at the angiotensin ii type 1 receptor reduces blood pressure and increases cardiac performance. J Pharmacol Exp Ther 2010, 335:572-579.
65. Bristow M.R. Beta-adrenergic receptor blockade in chronic heart failure. Circulation 2000, 101:558-569.
66. Noor N., Patel C.B., Rockman H.A. Beta-arrestin. A signaling molecule and potential therapeutic target for heart failure. J Mol Cell Cardiol 2011, 51:534-541.
67. Wisler J.W., DeWire S.M., Whalen E.J., Violin J.D., Drake M.T., Ahn S., Shenoy S.K., Lefkowitz R.J. A unique mechanism of beta-blocker action: carvedilol stimulates beta-arrestin signaling. Proc Natl Acad Sci U S A 2007, 104:16657-16662.
68. Shoichet B.K., Kobilka B.K. Structure-based drug screening for g-protein-coupled receptors. Trends Pharmacol Sci 2012, 33:268-272.
69. de Graaf C., Kooistra A.J., Vischer H.F., Katritch V., Kuijer M., Shiroishi M., Iwata S., Shimamura T., Stevens R.C., de Esch I.J., Leurs R. Crystal structure-based virtual screening for fragment-like ligands of the human histamine h(1) receptor. J Med Chem 2011, 54:8195-8206.
70. Kruse A.C., Weiss D.R., Rossi M., Hu J., Hu K., Eitel K., Gmeiner P., Wess J., Kobilka B.K., Shoichet B.K. Muscarinic receptors as model targets and antitargets for structure-based ligand discovery. Mol Pharmacol 2013, 84:528-540.
71. Langmead C.J., Andrews S.P., Congreve M., Errey J.C., Hurrell E., Marshall F.H., Mason J.S., Richardson C.M., Robertson N., Zhukov A., Weir M. Identification of novel adenosine a(2a) receptor antagonists by virtual screening. J Med Chem 2012, 55:1904-1909.
72. Nygaard R., Zou Y., Dror R.O., Mildorf T.J., Arlow D.H., Manglik A., Pan A.C., Liu C.W., Fung J.J., Bokoch M.P., Thian F.S., et al. The dynamic process of beta(2)-adrenergic receptor activation. Cell 2013, 152:532-542.
73. Rasmussen S.G., Choi H.J., Fung J.J., Pardon E., Casarosa P., Chae P.S., Devree B.T., Rosenbaum D.M., Thian F.S., Kobilka T.S., Schnapp A., et al. Structure of a nanobody-stabilized active state of the beta(2) adrenoceptor. Nature 2011, 469:175-180.
74. Rasmussen S.G., DeVree B.T., Zou Y., Kruse A.C., Chung K.Y., Kobilka T.S., Thian F.S., Chae P.S., Pardon E., Calinski D., Mathiesen J.M., et al. Crystal structure of the beta2 adrenergic receptor-gs protein complex. Nature 2011, 477:549-555.
75. Lebon G., Warne T., Edwards P.C., Bennett K., Langmead C.J., Leslie A.G., Tate C.G. Agonist-bound adenosine a2a receptor structures reveal common features of gpcr activation. Nature 2011, 474:521-525.
76. Dror R.O., Jensen M.O., Borhani D.W., Shaw D.E. Exploring atomic resolution physiology on a femtosecond to millisecond timescale using molecular dynamics simulations. J Gen Physiol 2010, 135:555-562.
77. Dror R.O., Arlow D.H., Maragakis P., Mildorf T.J., Pan A.C., Xu H., Borhani D.W., Shaw D.E. Activation mechanism of the beta2-adrenergic receptor. Proc Natl Acad Sci U S A 2011, 108:18684-18689.
78. Dror R.O., Pan A.C., Arlow D.H., Borhani D.W., Maragakis P., Shan Y., Xu H., Shaw D.E. Pathway and mechanism of drug binding to g-protein-coupled receptors. Proc Natl Acad Sci U S A 2011, 108:13118-13123.